α_1-Adrenoceptor antagonists, called α_1-blockers, are the first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Nonselective α_1-blockers like prazosin were mainly used in the past, but prostate-specific α_1-blockers such as tamsulosin or naftopidil are now the mainstream agents for the management of BPH, based on the function of α_1-adrenoceptor subtypes. Recent studies on voiding dysfunction have clarified the association between BPH and overactive bladder (OAB) , underlining the use of OAB treatment in the management of BPH, inducing the simultaneous administration of antimuscarinic agents. Every aspect of diversified BPH symptom can be controlled individually in a short period.